Expression And Clinical Significace Of Mage-D4, OY-TES-1, NY-SAR-35 In Glioma

PURPOSE To study the expression and significance of MAGE-D4, OY-TES-1, NY-SAR-35 in glioma and explore the possibility of using the 3 antigens as target antigen in glioma.METHODS Expression of the 3 antigens protein was detected by immunohistochemical method in 124 pathologically diagnosed glioma cases. The correlation between them and clinical pathological features of tumors was analyzed by SPSS 13.0 statistics analysis software.RESULTS(1) The expression rates of MAGE-D4 in glioma were 78.23%(97/124). According to the expression intensity,59.68%(74/124) of the specimens show high expression of MAGE-D4 protein (++/+++), and 40.32%(50/124) of the specimen is MAGE-D4 low expression (-/+).The expression of MAGE-D4 in glioma have correlation with the WHO classification, P53 expression (P<0.05). High expression of MAGE-D4 protein in patients have poor prognosis when compared to those with low expression of MAGE-D4 protein (P=0.019).(2) The expression rates of OY-TES-1 in glioma were 69.35% (86/124). According to the expression intensity,56.45% (70/124) of the specimens show high expression of OY-TES-1 protein (++/+++), and 43.55% (54/124) of the specimen is OY-TES-1 low expression (-/+).The expression of OY-TES-1 in glioma have correlation with the WHO classification, Ki-67 and P53 expression (P<0.05). High expression of OY-TES-1 protein in patients have poorer prognosis when compared with those with low expression of OY-TES-1 protein (P=0.024).(3) The expression rates of NY-SAR-35 in glioma were 45.97%(57/124). According to the expression intensity,29.03%(36/124) of the specimens show high expression of NY-SAR-35 protein (++/+++), and 70.97%(88/124) of the specimen is NY-SAR-35 low expression (-/+).The expression of NY-SAR-35 in glioma only has correlation with the WHO classification (P<0.05). High expression of NY-SAR-35 protein in patients have poorer prognosis when compared to those with low expression of NY-SAR-35 protein (P=0.042).(4) 13.71%(17/124) of the specimens do not express any kind of antigens. 86.29%(107/124) of the specimens express at least one of the antigens.41% (51/124) of the specimens express two antigens.33% (41/124) expressed all the three kinds of antigens at the same time.CONCLUSIONMAGE-D4, OY-TES-1 protein is expressed in glioma at a high frequency, NY-SAR-35 protein also has significant frequency expression rates in glioma. The patients with high expression of antigen protein have poor prognosis compare to those with low expression of antigen protein. In patients with glioma expressing all three kinds of antigen, the prognosis was worse compared to patients with all three antigens negative expressions. These results prompt that in future these three kinds of antigens can be added in preparation of tumor vaccine, improving the overall effect of tumor immunotherapy.